These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1893 related items for PubMed ID: 9506190

  • 21. The pathophysiologic basis of efficacy and clinical experience with the new oral antidiabetic agents.
    Rosak C.
    J Diabetes Complications; 2002; 16(1):123-32. PubMed ID: 11872380
    [Abstract] [Full Text] [Related]

  • 22. Prevention of complications in non-insulin-dependent diabetes mellitus (NIDDM).
    Wolffenbuttel BH, van Haeften TW.
    Drugs; 1995 Aug; 50(2):263-88. PubMed ID: 8521759
    [Abstract] [Full Text] [Related]

  • 23. United Kingdom Prospective Diabetes Study 17: a 9-year update of a randomized, controlled trial on the effect of improved metabolic control on complications in non-insulin-dependent diabetes mellitus.
    Turner R, Cull C, Holman R.
    Ann Intern Med; 1996 Jan 01; 124(1 Pt 2):136-45. PubMed ID: 8554206
    [Abstract] [Full Text] [Related]

  • 24. Pathophysiology of type 2 diabetes: rationale for different oral antidiabetic treatment strategies.
    Giorgino F, Laviola L, Leonardini A.
    Diabetes Res Clin Pract; 2005 Jun 01; 68 Suppl1():S22-9. PubMed ID: 15955371
    [Abstract] [Full Text] [Related]

  • 25. Cardiovascular manifestations of insulin resistance.
    Chahwala V, Arora R.
    Am J Ther; 2009 Jun 01; 16(5):e14-28. PubMed ID: 19114874
    [Abstract] [Full Text] [Related]

  • 26. Focus on insulin resistance in type 2 diabetes: therapeutic implications.
    Reusch JE.
    Diabetes Educ; 1998 Jun 01; 24(2):188-93. PubMed ID: 9555358
    [Abstract] [Full Text] [Related]

  • 27. [Repaglinide in combination therapy in type 2 diabetes].
    Moses R.
    Diabetes Metab; 1999 Dec 01; 25 Suppl 7():26-7. PubMed ID: 10746009
    [Abstract] [Full Text] [Related]

  • 28. Advancing therapy in type 2 diabetes mellitus with early, comprehensive progression from oral agents to insulin therapy.
    Vinik A.
    Clin Ther; 2007 Dec 01; 29 Spec No():1236-53. PubMed ID: 18046925
    [Abstract] [Full Text] [Related]

  • 29. [A 50-year history of new drugs in Japan-the development and progress of anti-diabetic drugs and the epidemiological aspects of diabetes mellitus].
    Ozawa H, Murai Y, Ozawa T.
    Yakushigaku Zasshi; 2003 Dec 01; 38(1):11-27. PubMed ID: 14570054
    [Abstract] [Full Text] [Related]

  • 30. Current treatment approaches to type 2 diabetes mellitus: successes and shortcomings.
    Collins FM.
    Am J Manag Care; 2002 Oct 01; 8(16 Suppl):S460-71. PubMed ID: 12408409
    [Abstract] [Full Text] [Related]

  • 31. Managing obesity and glycemic control in insulin-using patients: clinical relevance and practice recommendations.
    Gottesman I.
    Diabetes Res Clin Pract; 2004 Sep 01; 65 Suppl 1():S17-22. PubMed ID: 15315866
    [Abstract] [Full Text] [Related]

  • 32. Glucose supply and insulin demand dynamics of antidiabetic agents.
    Monte SV, Schentag JJ, Adelman MH, Paladino JA.
    J Diabetes Sci Technol; 2010 Mar 01; 4(2):365-81. PubMed ID: 20307399
    [Abstract] [Full Text] [Related]

  • 33. Potential new treatments for type 2 diabetes.
    Bailey CJ.
    Trends Pharmacol Sci; 2000 Jul 01; 21(7):259-65. PubMed ID: 10871894
    [Abstract] [Full Text] [Related]

  • 34. Pathophysiology of type 2 diabetes and modes of action of therapeutic interventions.
    Dagogo-Jack S, Santiago JV.
    Arch Intern Med; 1997 Sep 08; 157(16):1802-17. PubMed ID: 9290539
    [Abstract] [Full Text] [Related]

  • 35. [Progress in the prevention of type 2 diabetes].
    Schernthaner G.
    Wien Klin Wochenschr; 2003 Nov 28; 115(21-22):745-57. PubMed ID: 14743578
    [Abstract] [Full Text] [Related]

  • 36. EADSG Guidelines: Insulin Therapy in Diabetes.
    Silver B, Ramaiya K, Andrew SB, Fredrick O, Bajaj S, Kalra S, Charlotte BM, Claudine K, Makhoba A.
    Diabetes Ther; 2018 Apr 28; 9(2):449-492. PubMed ID: 29508275
    [Abstract] [Full Text] [Related]

  • 37. Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice.
    Tahara A, Kurosaki E, Yokono M, Yamajuku D, Kihara R, Hayashizaki Y, Takasu T, Imamura M, Li Q, Tomiyama H, Kobayashi Y, Noda A, Sasamata M, Shibasaki M.
    Eur J Pharmacol; 2013 Sep 05; 715(1-3):246-55. PubMed ID: 23707905
    [Abstract] [Full Text] [Related]

  • 38. The importance of first-phase insulin secretion: implications for the therapy of type 2 diabetes mellitus.
    Del Prato S, Tiengo A.
    Diabetes Metab Res Rev; 2001 Sep 05; 17(3):164-74. PubMed ID: 11424229
    [Abstract] [Full Text] [Related]

  • 39. Optimising therapy for insulin-treated type 2 diabetes mellitus.
    Hermann LS.
    Drugs Aging; 2000 Oct 05; 17(4):283-94. PubMed ID: 11087006
    [Abstract] [Full Text] [Related]

  • 40. Troglitazone: review and assessment of its role in the treatment of patients with impaired glucose tolerance and diabetes mellitus.
    Johnson MD, Campbell LK, Campbell RK.
    Ann Pharmacother; 1998 Mar 05; 32(3):337-48. PubMed ID: 9533065
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 95.